1. Efsitora is a once-weekly insulin therapy compared to daily degludec.
2. Study involved 986 adults over 78 weeks.
3. Efsitora showed a HbA1c reduction of 0.81% vs 0.72% for degludec.
4. Similar hypoglycemia rates were observed for both treatments.
5. Patient satisfaction increased with weekly dosing, reducing annual injections from 365 to 52.
6. Most adverse events were mild; serious events were uncommon.
7. Efsitora is a feasible alternative for adults with type 2 diabetes on basal insulin.

Source: The Lancet